Subscribe Become an Author Add Company Sign Up Log In

White Matter Communications

Contributor News

White Matter Communications (WMC) was founded in 2016 to create connections and build brand recognition via thoughtful communication programs in the life sciences industry.

     

Biologics Biopharma news Mobile Technologies Pharma 4.0 Pharmaceutical industry trends R&D Outsourcing Cell Therapies

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Exyte and Univercells Technologies Combine Аorces for Rapid Deployment of Vaccine Production Plants in the Wake of the COVID-19 Pandemic

   106
  • Exyte offers the new ExyCellR modular technology for fast-track construction of biologicals production facilities compliant with the current good manufacturing practice (cGMP).
  • Univercells Technologies delivers the integrated NevoLine™ biomanufacturing platform, including scale-X™ bioreactors, for low footprint and economic large-scale production of viral products.
  • The combined offer enables users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to new disease outbreaks.

Introducing Univercells Technologies, Univercells’ subsidiary focused on the development and commercialization of intensified, automated biomanufacturing technologies

   79
Introducing Univercells Technologies, Univercells’ subsidiary focused on the development and commercialization of intensified, automated biomanufacturing technologies

Brussels, Belgium, May 05, 2020 – Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today.  Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market.  

C2 PHARMA Expands Advisory Board To Support Growth Objectives

   55

Luxembourg, March 3, 2020C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has expanded their advisory board with a new member. Consisting of well-respected pharmaceutical industry experts, the board provides strategic guidance on the progress and growth of the company via organic and M&A activities in the mid and long-term.